(AXSM) Axsome Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043

Antidepressant, Anti-Sleepiness, Migraine, Alzheimer, Narcolepsy

Pharmaceuticals
Market Cap in USD: 8,447m
IPO / Inception: 2015-11-19
12m vs SPY: 57.1%

EPS (Earnings per Share)

EPS (Earnings per Share) of AXSM over the last years for every Quarter: "2020-12": -0.78, "2021-03": -0.78, "2021-06": -0.86, "2021-09": -0.93, "2021-12": -0.9, "2022-03": -1.03, "2022-06": -1.06, "2022-09": -1.07, "2022-12": -1.41, "2023-03": -0.26, "2023-06": -1.54, "2023-09": -1.32, "2023-12": -2.08, "2024-03": -1.44, "2024-06": -1.67, "2024-09": -1.3419, "2024-12": -1.54, "2025-03": -1.2157, "2025-06": -0.97, "2025-09": -0.94,
EPS CAGR: -0.83%
EPS Trend: -22.2%
Last SUE: -0.33
Qual. Beats: 0

Revenue

Revenue of AXSM over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 8.82, 2022-09: 16.846, 2022-12: 24.371528, 2023-03: 94.576, 2023-06: 46.7, 2023-09: 57.794, 2023-12: 71.53, 2024-03: 74.999, 2024-06: 87.166, 2024-09: 104.762, 2024-12: 118.766, 2025-03: 121.463, 2025-06: 150.042, 2025-09: 170.992,
Rev. CAGR: 134.25%
Rev. Trend: 83.5%
Last SUE: 2.02
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 46.5%
Value at Risk 5%th 68.2%
Relative Tail Risk -10.85%
Reward TTM
Sharpe Ratio 1.61
Alpha 88.08
CAGR/Max DD 1.00
Character TTM
Hurst Exponent 0.488
Beta 0.657
Beta Downside 0.806
Drawdowns 3y
Max DD 36.45%
Mean DD 14.00%
Median DD 14.16%

Description: AXSM Axsome Therapeutics January 08, 2026

Axsome Therapeutics (NASDAQ: AXSM) is a U.S.-based biopharma focused on central nervous system (CNS) disorders. Its approved portfolio includes Auvelity (dextromethorphan-bupropion) for major depressive disorder, Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea, and Symbravo (AXS-07), a rapid-onset migraine treatment combining meloxicam and rizatriptan.

The pipeline leverages the same dextromethorphan-bupropion platform (AXS-05) and other norepinephrine-focused agents. AXS-05 has finished Phase III trials for Alzheimer’s disease agitation and Phase II for smoking cessation; AXS-12 completed Phase III in narcolepsy; AXS-14 wrapped Phase III for fibromyalgia; and Solriamfetol is in Phase III for ADHD, major depression, binge-eating disorder, and shift-work sleepiness. Axsome also maintains a research collaboration with Duke University to explore AXS-05 in smoking cessation.

As of Q4 2023, Axsome reported $115 million in revenue, a cash runway of roughly $300 million, and a net loss of $150 million, reflecting heavy R&D spend. The CNS therapeutic market is expanding at ~6 % CAGR, driven by aging demographics and increasing diagnosis rates, but pricing pressure from insurers and competition from larger players (e.g., Johnson & Johnson, Eli Lilly) remain material risk factors.

For a deeper, data-driven assessment of AXSM’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-229.5m TTM) > 0 and > 6% of Revenue (6% = 33.7m TTM)
FCFTA -0.15 (>2.0%) and ΔFCFTA 8.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 36.53% (prev 83.59%; Δ -47.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.15 (>3.0%) and CFO -101.0m > Net Income -229.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (50.0m) change vs 12m ago 3.91% (target <= -2.0% for YES)
Gross Margin 91.86% (prev 91.09%; Δ 0.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 91.21% (prev 60.28%; Δ 30.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -29.04 (EBITDA TTM -212.3m / Interest Expense TTM 7.59m) >= 6 (WARN >= 3)

Altman Z'' -8.87

(A) 0.31 = (Total Current Assets 565.3m - Total Current Liabilities 360.3m) / Total Assets 669.2m
(B) -1.91 = Retained Earnings (Balance) -1.28b / Total Assets 669.2m
warn (B) unusual magnitude: -1.91 — check mapping/units
(C) -0.36 = EBIT TTM -220.5m / Avg Total Assets 615.4m
(D) -2.15 = Book Value of Equity -1.28b / Total Liabilities 595.5m
Total Rating: -8.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.38

1. Piotroski 3.0pt
2. FCF Yield -1.21%
3. FCF Margin -18.00%
4. Debt/Equity 2.96
5. Debt/Ebitda 0.50
6. ROIC - WACC (= -96.86)%
7. RoE -357.2%
8. Rev. Trend 83.52%
9. EPS Trend -22.23%

What is the price of AXSM shares?

As of January 12, 2026, the stock is trading at USD 169.38 with a total of 772,933 shares traded.
Over the past week, the price has changed by -1.23%, over one month by +13.87%, over three months by +39.81% and over the past year by +89.74%.

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
  • Strong Buy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AXSM price?

Issuer Target Up/Down from current
Wallstreet Target Price 197.6 16.7%
Analysts Target Price 197.6 16.7%
ValueRay Target Price 229.7 35.6%

AXSM Fundamental Data Overview January 10, 2026

P/E Forward = 285.7143
P/S = 15.0493
P/B = 114.5664
Beta = 0.433
Revenue TTM = 561.3m USD
EBIT TTM = -220.5m USD
EBITDA TTM = -212.3m USD
Long Term Debt = 117.6m USD (from longTermDebt, last quarter)
Short Term Debt = 73.2m USD (from shortTermDebt, last quarter)
Debt = 218.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -106.7m USD (from netDebt column, last quarter)
Enterprise Value = 8.34b USD (8.45b + Debt 218.6m - CCE 325.3m)
Interest Coverage Ratio = -29.04 (Ebit TTM -220.5m / Interest Expense TTM 7.59m)
EV/FCF = -82.54x (Enterprise Value 8.34b / FCF TTM -101.0m)
FCF Yield = -1.21% (FCF TTM -101.0m / Enterprise Value 8.34b)
FCF Margin = -18.00% (FCF TTM -101.0m / Revenue TTM 561.3m)
Net Margin = -40.89% (Net Income TTM -229.5m / Revenue TTM 561.3m)
Gross Margin = 91.86% ((Revenue TTM 561.3m - Cost of Revenue TTM 45.7m) / Revenue TTM)
Gross Margin QoQ = 93.03% (prev 91.04%)
Tobins Q-Ratio = 12.46 (Enterprise Value 8.34b / Total Assets 669.2m)
Interest Expense / Debt = 0.51% (Interest Expense 1.12m / Debt 218.6m)
Taxrate = -0.0% (0.0 / -47.2m)
NOPAT = -220.5m (EBIT -220.5m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 1.57 (Total Current Assets 565.3m / Total Current Liabilities 360.3m)
Debt / Equity = 2.96 (Debt 218.6m / totalStockholderEquity, last quarter 73.7m)
Debt / EBITDA = 0.50 (negative EBITDA) (Net Debt -106.7m / EBITDA -212.3m)
Debt / FCF = 1.06 (negative FCF - burning cash) (Net Debt -106.7m / FCF TTM -101.0m)
Total Stockholder Equity = 64.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.30% (Net Income -229.5m / Total Assets 669.2m)
RoE = -357.2% (Net Income TTM -229.5m / Total Stockholder Equity 64.3m)
RoCE = -121.2% (out of range, set to none) (EBIT -220.5m / Capital Employed (Equity 64.3m + L.T.Debt 117.6m))
RoIC = -88.72% (negative operating profit) (NOPAT -220.5m / Invested Capital 248.6m)
WACC = 8.14% (E(8.45b)/V(8.67b) * Re(8.34%) + D(218.6m)/V(8.67b) * Rd(0.51%) * (1-Tc(-0.0)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.80%
Fair Price DCF = unknown (Cash Flow -101.0m)
EPS Correlation: -22.23 | EPS CAGR: -0.83% | SUE: -0.33 | # QB: 0
Revenue Correlation: 83.52 | Revenue CAGR: 134.3% | SUE: 2.02 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.67 | Chg30d=-0.062 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=0.39 | Chg30d=+0.129 | Revisions Net=+1 | Growth EPS=+110.0% | Growth Revenue=+57.1%

Additional Sources for AXSM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle